Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors

• DOI: 10.1038/s41541-019-0149-x
• Publication Date: 2020-01-16T11:04:55Z
• Authors: Friedrich Erhart; Matthias Hackl; Hannes Hahne; Johanna Buchroithner; Chen Meng; Simone Klingenbru...; René Reitermaier; Katrin Fischhuber; Susanna Skalicky; Walter Berger; Sabine Spiegl-Kre...; Daniela Lötsch; Gerda Ricken; Bernhard Kuster; Adelheid Wöhrer; Georg Widhalm; Johannes Hainfellner; Thomas Felzmann; Alexander M. Dohnal; Christine Marosi; Carmen Visus
• Keywords: 0303 health sciences; 03 medical and health sciences; Article; 3. Good health

Abstract Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15–20 months under standard therapy, novel treatment approaches are desperately needed. A recent phase II clinical trial with personalized immunotherapy based on tumor lysate-charged dendritic cell (DC) vaccination, however, failed to prolong survival. Here, we investigated tissue from patients explore glioblastoma survival-related factors. We followed an innovative approach combining mass spectrometry-based quantitative proteomics ( n = 36) microRNA sequencing plus RT-qPCR 38). Protein quantification identified, e.g., huntingtin interacting protein 1 (HIP1), retinol-binding (RBP1), ferritin heavy chain (FTH1) focal adhesion kinase 2 (FAK2) as factor candidates correlated dismal prognosis. MicroRNA analysis identified miR-216b, miR-216a, miR-708 let-7i molecules potentially associated favorable characteristics they were enriched in comparably longer To illustrate utility integrated miRNomics findings, was studied further one example for pathway potential general interest. Taken together, here mapped possible drivers outcome largest DC vaccination cohorts so far—demonstrating usefulness feasibility combined proteomics/miRNomics approaches. Future research should investigate agents that sensitize (immuno)therapy—potentially building insights generated here.